Molnupiravir for treatment of adults with mild or moderate COVID-19: a systematic review and meta-analysis of randomized controlled trials
Y Gao, M Liu, Z Li, J Xu, J Zhang, J Tian - Clinical Microbiology and …, 2023 - Elsevier
Background The effects of molnupiravir in treating patients with non-severe COVID-19
remain uncertain. Objectives To evaluate the efficacy and safety of molnupiravir in adult …
remain uncertain. Objectives To evaluate the efficacy and safety of molnupiravir in adult …
Efficacy and safety of molnupiravir treatment for COVID-19: a systematic review and meta-analysis of randomized controlled trials
F Tian, Q Feng, Z Chen - International Journal of Antimicrobial Agents, 2023 - Elsevier
Introduction There are currently some differences in the research results of molnupiravir.
This study aimed to evaluate the efficacy and safety of molnupiravir in the treatment of …
This study aimed to evaluate the efficacy and safety of molnupiravir in the treatment of …
[HTML][HTML] Efficacy of Molnupiravir for the treatment of mild or moderate COVID-19 in adults: a meta-analysis
The aim of this meta-analysis is to evaluate the efficacy of molnupiravir among mild or
moderate COVID-19 patients. This meta-analysis was reported according to the guidelines …
moderate COVID-19 patients. This meta-analysis was reported according to the guidelines …
Clinical efficacy and safety of molnupiravir for nonhospitalized and hospitalized patients with COVID‐19: a systematic review and meta‐analysis of randomized control …
The efficacy of molnupiravir in treating patients with coronavirus disease 2019 (COVID‐19)
has been inconsistent across randomized controlled trials (RCTs). Thus, this meta‐analysis …
has been inconsistent across randomized controlled trials (RCTs). Thus, this meta‐analysis …
Efficacy and safety of antiviral treatments for symptomatic COVID-19 outpatients: Systematic review and network meta-analysis
M Zur, T Peselev, S Yanko, V Rotshild, I Matok - Antiviral Research, 2023 - Elsevier
Background Remdesivir, molnupiravir, and nirmatrelvir/ritonavir are three antiviral agents
approved by FDA emergency authorization for treating mild to moderate symptomatic COVID …
approved by FDA emergency authorization for treating mild to moderate symptomatic COVID …
Molnupiravir for the treatment of non-severe COVID-19: a systematic review and meta-analysis of 14 randomized trials with 34 570 patients
M Sun, H Lai, J Huang, J Liu, Y Li, J Tian… - Journal of …, 2023 - academic.oup.com
Background Molnupiravir has been considered a promising candidate for COVID-19. Its
efficacy and safety in non-severe COVID-19 patients and the differences between patients …
efficacy and safety in non-severe COVID-19 patients and the differences between patients …
Impact of some antiviral drugs on health care utilization for patients with COVID-19: a systematic review and meta-analysis
B Wei, R Zhang, H Zeng, L Wu, R He… - Expert Review of Anti …, 2023 - Taylor & Francis
Background We aimed to assess the impact of antiviral drugs (fluvoxamine, remdesivir,
lopinavir/ritonavir (LPV/r), molnupiravir, andnirmatrelvir/ritonavir (NRV/r)) on health care …
lopinavir/ritonavir (LPV/r), molnupiravir, andnirmatrelvir/ritonavir (NRV/r)) on health care …
The relationship between viral clearance rates and disease progression in early symptomatic COVID-19: a systematic review and meta-regression analysis
S Singh, S Boyd, WHK Schilling… - Journal of …, 2024 - academic.oup.com
Background Effective antiviral drugs accelerate viral clearance in acute COVID-19
infections; the relationship between accelerating viral clearance and reducing severe …
infections; the relationship between accelerating viral clearance and reducing severe …
Adverse events associated with molnupiravir: a real-world disproportionality analysis in food and drug administration adverse event reporting system
Y Liang, L Ma, Y Wang, J Zheng, L Su… - Frontiers in …, 2023 - frontiersin.org
Molnupiravir, an urgently approved drug during the Coronavirus Disease 2019 (COVID-19)
pandemic, serves as the basis for our study, which relies on the Food and Drug …
pandemic, serves as the basis for our study, which relies on the Food and Drug …